Celltrion Files Subcutaneous Infliximab In US – As Standalone BLA

‘Biobetter’ Submitted To FDA As Biologic Via 351(a) Pathway, Not As A Biosimilar

 
• By David Wallace
FDA building.
Celltrion has filed its subcutaneous infliximab with the FDA • Source: Shutterstock

More from Biosimilars

More from Products